title: Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance.
abstract: OBJECTIVE
  To study the expression of intercellular adhesion molecule-1 (ICAM-1) by non-Hodgkin's lymphomas and to assess its correlation with disease extension and prognosis.
  
  
  METHODS
  ICAM-1 (CD54-IOL54) expression was studied in 70 patients (35 male/35 female; median age, 56 years) with non-Hodgkin's lymphoma from a single institution. Immunostaining was performed using a streptavidine-biotin alkaline phosphatase method and ICAM-1 expression was evaluated in a semiquantitative manner. The histologic distribution of the cases was the following: small lymphocytic, five cases; follicular, 14; mantle cell, five; diffuse large cell, 41; and T lymphoblastic, five. Forty patients (57%) were in stage IV, bulky disease was observed in 25 patients (36%), and extranodal involvement in 48 patients (69%).
  
  
  RESULTS
  ICAM-1 expression was negative (-) in 14 patients (20%), weak (+) in 21 (30%), positive (++) in 30 (43%), and strongly positive ( ) in five (7%). No significant relationship was found between ICAM-1 expression and the lymphoma histologic subtype. Patients with negative or weak ICAM-1 expression had more frequently disseminated (stage IV) disease (74% v 40%; P = .007), extranodal involvement (86% v 51%; P = .004), and bone marrow infiltration (57% v 26%; P = .015) than the remainders. Positive ICAM-1 patients had survival rates significantly better than those in whom ICAM-1 was negative or weakly expressed [2-year overall survival: 77% v 50%, respectively; P < .025]. In a multivariate study, ICAM-1 (P = .005) maintained, along with histologic subtype (P = .001) and the international prognostic index (IPI) (P = .056), its importance for predicting survival. Finally, when the group of aggressive non-Hodgkin's lymphoma patients was analyzed, ICAM-1 expression inversely correlated with advanced stage (P = .025), extranodal involvement (P = .01), and bone marrow infiltration (P = .01), complete response (CR) achievement (65% v 32%; P = .025), and overall survival (70% v 26% at 2 years; P < .005).
  
  
  CONCLUSIONS
  In lymphoma patients, ICAM-1 expression correlates with lymphoma dissemination and is useful to assess prognosis.
authors.affiliation: Postgraduate School of Hematology Farreras Valenti, and Department of Internal Medicine, Hospital Clinic of Barcelona, Spain.
authors.forename: M J
authors.initials: MJ
authors.lastname: Terol
authors.forename: A
authors.initials: A
authors.lastname: López-Guillermo
authors.forename: F
authors.initials: F
authors.lastname: Bosch
authors.forename: N
authors.initials: N
authors.lastname: Villamor
authors.forename: M C
authors.initials: MC
authors.lastname: Cid
authors.forename: C
authors.initials: C
authors.lastname: Rozman
authors.forename: E
authors.initials: E
authors.lastname: Campo
authors.forename: E
authors.initials: E
authors.lastname: Montserrat
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000951:Antigens, Neoplasm / Q000378:metabolism*; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism*; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D000951:Antigens, Neoplasm; D018799:Intercellular Adhesion Molecule-1